Type of non Hodgkin's lymphoma-Other-Marginal zone B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Marginal zone B-cell lymphoma Posts on Medivizor

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating SCR chemotherapy for patients with non-Hodgkin’s lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).   This study concluded that this combination appears safe and effective for these patients.   Some background Patients...

Read More

Evaluating the impact of autoimmune conditions on the outcomes of patients with lymphoma

Posted by on Dec 13, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of autoimmune conditions on the outcomes of patients with lymphoma. This study concluded that these conditions may negatively impact survival outcomes for these patients. Some background Autoimmune conditions are a group of diseases where the immune system attacks the body’s healthy tissues. One...

Read More

Evaluating the impact of autoimmune conditions on the outcomes of patients with lymphoma

Posted by on Dec 13, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the impact of autoimmune conditions on the outcomes of patients with lymphoma. This study concluded that these conditions may negatively impact survival outcomes for these patients. Some background Autoimmune conditions are a group of diseases where the immune system attacks the body’s healthy tissues. One...

Read More

Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma

Posted by on Sep 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...

Read More

Evaluating venetoclax with BR for the treatment of relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Aug 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...

Read More

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Posted by on May 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...

Read More

Looking for patients with relapsed or refractory B-cell lymphoma to test the effectiveness of radioimmunotherapy followed by chemotherapy before stem cell transplant

Posted by on Sep 11, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of yttrium-90 (Y-90)-ibritumomab tiuxetan (Zevalin) followed by fludarabine (Fludara), total body irradiation, and donor peripheral blood stem cell transplant (PBSCT) in patients with relapsed or refractory (did not respond to treatment) B-cell lymphoma. The primary...

Read More